In the past week, the Leap Therapeutics Inc (NASDAQ:LPTX) stock has emerged as one of the stronger performers and the trend continued on Wednesday. Yesterday, the Leap Therapeutics stock ended the day with gains of 8% and that took its cumulative gains for the past week to as much as 24%.
There was no news about the company yesterday but earlier on in the week Leap Therapeutics announced that it got positive data from the Phase 2a clinical trial into its product DKN-01, which is an anti-Dickkopf-1 antibody and is meant for cancer treatment.
It seems that the announcement with regards to positive data earlier on this week proved to be the reason behind the optimism among investors. Leap Therapeutics announced that the patients who had the highest levels of DKN1 levels actually demonstrated the highest rates of response.
That was an important observation and one that could have come as a major boost for the stock. It should be noted that the study in question is currently being conducted in South Korea and United States. Considering the price action in the Leap Therapeutics stock over the course of the past few days, it might be the right time to add the stock to your watch lists.
